Skip to content

US · UPC · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Universe Pharmaceuticals Inc. (UPC) intrinsic value and stock valuation

$1.08as of 2026-11-21 · Mkt cap 3.89M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Universe Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values UPC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from UPC’s statements →

Universe Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Ji'An, JX 343100 universe-pharmacy.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$17.9M-10.3% 5y CAGRd
20182025
Net income
-$-3.67M
20182025
Free cash flow
-$-5.4M
20182025
Total equity
$56.1M+22% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$17.9M$23M$32.3M$40.1M$48M
Operating income-$-2.92M-$-8.02M-$-3.53M-$-7.02M$13.6M
Net income-$-3.67M-$-8.73M-$-6.16M-$-8.74M$11.3M
EPSd—-$-873M-$-616M-$-874M$1.13B
Operating cash flow-$-5.05M-$-9.51M$1.12M-$-1.31M-$-2.06M
Capital expenditure-$-350K-$-360K-$-40K-$-90K-$-13.53M
Free cash flow-$-5.4M-$-9.87M$1.08M-$-1.41M-$-15.59M
Total assets$69.3M$68M$53.3M$59.5M$70.1M
Total debt$9.26M$7.99M$5.48M$3.94M$4.33M
Net debt-$-24.34M-$-21.5M$200K-$-1.78M-$-3.74M
Total equity$56.1M$45.5M$39.5M$46.4M$58.9M
Cash and short-term investments$33.6M$29.5M$18.5M$18.9M$21.8M
Income statement
20252024202320222021
Revenue$17.9M$23M$32.3M$40.1M$48M
Cost of revenue$11.6M$17M$22M$18.3M$22.7M
Gross profit$6.3M$6.07M$10.3M$21.9M$25.3M
Research and development expenses$670K$3.03M$4.86M$7.62M$5.47M
Selling, general and administrative expenses$8M$10.4M$9M$21.3M$6.27M
Other expenses$540K$620K-$-20K-$-10K$230K
Operating expenses$9.22M$14.1M$13.8M$28.9M$11.7M
Cost and expenses$20.8M$31M$36.3M$47.2M$34.4M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$230K$280K$160K$160K$100K
Depreciation and amortization$520K$490K$510K$530K$450K
Ebitda-$-2.92M-$-7.36M-$-3.18M-$-6.4M$14.2M
Operating income-$-2.92M-$-8.02M-$-3.53M-$-7.02M$13.6M
Total other income/expenses, net-$-760K-$-100K-$-410K-$-550K$60K
Income before tax-$-3.67M-$-8.12M-$-3.94M-$-7.98M$13.7M
Income tax expense$0.00$610K$2.25M$750K$2.36M
Net income-$-3.67M-$-8.73M-$-6.16M-$-8.74M$11.3M
Weighted average shares outstanding$0.00$10K$10K$10K$10K
Weighted average diluted shares outstanding$0.00$10K$10K$10K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$33.6M$29.5M$18.5M$18.9M$21.8M
Net receivables$13.2M$17.9M$10.7M$15.2M$15.8M
Inventory$2.19M$1.74M$3.34M$2.21M$2.46M
Total current assets$53.6M$51.6M$36.8M$41.5M$50.5M
Property, plant and equipment, net$14.7M$15.3M$15M$13.6M$15.4M
Goodwill and intangible assets$300K$260K$150K$160K$180K
Long-term investments$700K$710K$690K$700K$740K
Total non-current assets$15.7M$16.3M$16.5M$18M$19.7M
Total assets$69.3M$68M$53.3M$59.5M$70.1M
Accounts payable$1.67M$4.91M$4.59M$3.08M$5.31M
Short-term debt$9.26M$5.86M$5.48M$3.94M$4.33M
Deferred revenue$40K$0.00$0.00$0.00$0.00
Total current liabilities$13.2M$20.3M$13.8M$13.1M$11.2M
Long-term debt$0.00$2.14M$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$2.14M$0.00$7.01M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$13.2M$22.5M$13.8M$13.1M$11.2M
Common stock$6.34M$480K$70K$70K$70K
Retained earnings-$-13.84M-$-10.17M$10.2M$16.3M$25.1M
Accumulated other comprehensive income (loss)$630K$1.33M$30K$770K$4.53M
Total equity$56.1M$45.5M$39.5M$46.4M$58.9M
Total investments$700K$710K$13.9M$13.9M$14.5M
Total debt$9.26M$7.99M$5.48M$3.94M$4.33M
Net debt-$-24.34M-$-21.5M$200K-$-1.78M-$-3.74M
Cash flow statement
20252024202320222021
Net income-$-3.67M-$-8.73M-$-6.58M-$-7.91M$11.3M
Depreciation and amortization$520K$490K$510K$530K$450K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-2.27M-$-2.06M$5.67M$6.6M-$-12.69M
Accounts receivable$3.13M-$-1.71M$4.72M-$-1.55M-$-3.87M
Inventory-$-470K$1.64M-$-1.18M$20K-$-450K
Accounts payable-$-3.13M$140K$1.64M-$-1.9M$2.46M
Net cash provided by operating activities-$-5.05M-$-9.51M$1.12M-$-1.31M-$-2.06M
Investments in property, plant and equipment-$-270K-$-250K-$-40K-$-90K-$-13.53M
Acquisitions, net$0.00$0.00$0.00-$-3.81M$26.6M
Net cash used for investing activities-$-340K-$-360K-$-40K-$-3.91M-$-27.06M
Common stock issued$15M$25M$0.00$0.00$28.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.73M$34M-$-1.39M$3.32M$26.6M
Net change in cash$4.09M$24.2M-$-430K-$-2.37M-$-1.98M
Cash at end of period$33.6M$29.5M$5.29M$5.71M$8.08M
Operating cash flow-$-5.05M-$-9.51M$1.12M-$-1.31M-$-2.06M
Capital expenditure-$-350K-$-360K-$-40K-$-90K-$-13.53M
Free cash flow-$-5.4M-$-9.87M$1.08M-$-1.41M-$-15.59M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Universe Pharmaceuticals Inc.

        Universe Pharmaceuticals Inc. (UPC) operates as a pharmaceutical enterprise primarily focused on the Chinese market. The company specializes in the production, promotion, and sale of products derived from traditional Chinese medicine (TCM). These remedies are designed to address common chronic health issues prevalent among the elderly, promoting physical well-being and longevity, in addition to offering medications for cold and flu symptoms. Beyond its own manufactured goods, UPC also functions as a distributor and vendor for a diverse range of third-party products. This extensive portfolio includes biomedical drugs, medical instruments, traditional Chinese medicine 'pieces' (raw ingredients), and various dietary supplements. Its clientele spans across the healthcare sector, encompassing other pharmaceutical companies, hospitals, clinics, and major drugstore chains. Established in 2019, the company's operations are headquartered in Ji'An, China, and it functions as a subsidiary of Sununion Holding Group Limited.

        CEO
        Gang Lai
        Employees
        216
        Beta
        1.46

        Explore

        Frequently asked questions

        What is the intrinsic value of Universe Pharmaceuticals Inc. (UPC)?

        InvestorsCraft does not currently publish an intrinsic value for UPC. How the IC value is calculated.

        Is UPC undervalued?

        InvestorsCraft does not publish an undervaluation signal for UPC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.